Literature DB >> 12702807

Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease.

Eileen Foy1, Kui Li, Chunfu Wang, Rhea Sumpter, Masanori Ikeda, Stanley M Lemon, Michael Gale.   

Abstract

Persistent infections with hepatitis C virus (HCV) are likely to depend on viral inhibition of host defenses. We show that the HCV NS3/4A serine protease blocks the phosphorylation and effector action of interferon regulatory factor-3 (IRF-3), a key cellular antiviral signaling molecule. Disruption of NS3/4A protease function by mutation or a ketoamide peptidomimetic inhibitor relieved this blockade and restored IRF-3 phosphorylation after cellular challenge with an unrelated virus. Furthermore, dominant-negative or constitutively active IRF-3 mutants, respectively, enhanced or suppressed HCV RNA replication in hepatoma cells. Thus, the NS3/4A protease represents a dual therapeutic target, the inhibition of which may both block viral replication and restore IRF-3 control of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12702807     DOI: 10.1126/science.1082604

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  298 in total

Review 1.  Induction and evasion of innate antiviral responses by hepatitis C virus.

Authors:  Stanley M Lemon
Journal:  J Biol Chem       Date:  2010-05-10       Impact factor: 5.157

2.  Hematopoietic growth factors for acute myelogenous leukemia.

Authors:  Matt Kalaycio
Journal:  Curr Hematol Rep       Date:  2004-01

3.  Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: Implications for virus evolution and host persistence.

Authors:  Peter Simmonds; Andrew Tuplin; David J Evans
Journal:  RNA       Date:  2004-07-23       Impact factor: 4.942

Review 4.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

5.  Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.

Authors:  Yueh-Ming Loo; David M Owen; Kui Li; Andrea K Erickson; Cynthia L Johnson; Penny M Fish; D Spencer Carney; Ting Wang; Hisashi Ishida; Mitsutoshi Yoneyama; Takashi Fujita; Takeshi Saito; William M Lee; Curt H Hagedorn; Daryl T-Y Lau; Steven A Weinman; Stanley M Lemon; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

6.  Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.

Authors:  Ju-Tao Guo; Qing Zhu; Christoph Seeger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  The induction of type I interferon production in hepatitis C-infected patients.

Authors:  Lawrence M Pfeffer; Margaret A Madey; Caroline A Riely; Jaquelyn F Fleckenstein
Journal:  J Interferon Cytokine Res       Date:  2009-05       Impact factor: 2.607

8.  Rotavirus nonstructural protein 1 subverts innate immune response by inducing degradation of IFN regulatory factor 3.

Authors:  Mario Barro; John T Patton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-01       Impact factor: 11.205

9.  Treatment of hepatitis C with an interferon-based lead-in phase: a perspective from mathematical modelling.

Authors:  Libin Rong; Jeremie Guedj; Harel Dahari; Alan S Perelson
Journal:  Antivir Ther       Date:  2014-01-16

Review 10.  Immune responses to HCV and other hepatitis viruses.

Authors:  Su-Hyung Park; Barbara Rehermann
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.